Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENCEPT 10/11-28 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Female contraception
Prevention of pregnancy
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol: primarily CYP3A4; Levonorgestrel: CYP3A4, undergoes reduction and sulfation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
98% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.8-1.0 L/kg, indicating extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral bioavailability is approximately 90%, with minimal first-pass metabolism.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 m L/min), use with caution due to potential fluid retention and hypertension.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in patients with Child-Pugh class B or C hepatic impairment (moderate to severe). In mild hepatic impairment (Child-Pugh class A), use with caution due to altered hormone metabolism.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, follow same dosing as adults.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in women above 55 years of age due to increased risk of thromboembolic events and lack of efficacy data.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI),Visual abnormalities (retinal thrombosis, papilledema),Hepatic neoplasia (benign/malignant liver tumors),Hypertension,Glucose intolerance/diabetes,Gallbladder disease,Depression,Bleeding irregularities
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food interactions are known. However, grapefruit juice may increase ethinyl estradiol levels; consider limiting grapefruit juice intake. Avoid excessive alcohol, as it may increase liver toxicity risk.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
GENCEPT 10/11-28 contains gestodene and ethinylestradiol. Gestodene is a progestogen; ethinylestradiol is an estrogen. Combined hormonal contraceptives are contraindicated in pregnancy. First trimester: no increased risk of major birth defects based on epidemiological studies, but should not be used once pregnancy is confirmed. Second and third trimesters: no therapeutic indication; animal studies show fetotoxicity at high doses. Overall, use is not recommended in pregnancy.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Gestodene and ethinylestradiol are excreted in breast milk in small amounts. The M/P ratio for ethinylestradiol is approximately 0.02; for gestodene, it is unknown but likely low. Combined hormonal contraceptives may reduce milk production and composition, especially in early lactation; use is generally not recommended during breastfeeding, particularly in the first 6 months postpartum. Progestin-only alternatives are preferred.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dose adjustment is applicable as the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) would theoretically reduce ethinylestradiol and gestodene levels, but since the drug is not used in pregnancy, no dosing recommendations are made.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
GENCEPT 10/11-28 is a combination oral contraceptive containing ethinyl estradiol 10 mcg and drospirenone 3 mg (24 active tablets) plus placebo (4 tablets). It is used for contraception and treatment of moderate acne vulgaris in women who desire oral contraception. The 24-day active regimen increases ovarian suppression and reduces breakthrough bleeding. Drospirenone has antimineralocorticoid activity, which may cause hyperkalemia in patients with renal impairment, hepatic disease, or adrenal insufficiency. Monitor potassium in at-risk patients. Do not use with other potassium-sparing drugs. Avoid in women with hypertension, diabetes with vascular disease, or migraine with aura due to increased cardiovascular risk with low-dose EE. Consider starting on first day of menses for immediate contraceptive effect.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time, in the order shown on the pack. Do not skip pills.,Use backup contraception (e.g., condoms) if you miss a pill, vomit within 3-4 hours after taking a pill, or have severe diarrhea.,Contact your doctor immediately if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Cigarette smoking increases the risk of serious cardiovascular side effects. Do not smoke while taking this medication.,Store at room temperature, away from moisture and heat.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENCEPT 10/11-28 vs ALYACEN 7/7/7, answered by our medical review team.
GENCEPT 10/11-28 is a Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENCEPT 10/11-28 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENCEPT 10/11-28 is: One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENCEPT 10/11-28 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENCEPT 10/11-28 is classified as Category C. GENCEPT 10/11-28 contains gestodene and ethinylestradiol. Gestodene is a progestogen; ethinylestradiol is an estrogen. Combined hormonal contraceptives are contraindicated in pregn. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.